ClinicalTrials.gg
TerminatedNCT02704403RESOLVE-ITUpdated Mar 23, 2022Results posted

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

A Phase 3 interventional study of Elafibranor and Placebo in Nonalcoholic Steatohepatitis (NASH) With Fibrosis, sponsored by Genfit. Terminated at 326 sites in 25 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-03-23.

Sponsored by Genfit · Phase 3, Interventional, and Treatment

Why this study was terminated
Study did not meet the predefined primary surrogate efficacy endpoint, no safety issues identified

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,157
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
5th of 460
2,157 · median 56
Started
2016
with 27 others
Phase 3
29 of 547
7 open now
Registered
171st of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 5th largest by enrollment of the 460 interventional ones that give a count, is one of 28 that started in 2016, is one of 29 in phase 3, and was the 171st registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 323 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 220 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 125 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

03

Conditions studied

  • Nonalcoholic Steatohepatitis (NASH) With Fibrosis

Keywords

  • Elafibranor
  • NASH
  • Nonalcoholic steatohepatitis
  • Fatty liver disease
  • Fibrosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females aged from 18 to 75 years inclusive at first screening visit.
  2. Must provide signed written and agree to comply with the study protocol.
  3. Females participating in this study must be of nonchildbearing potential or using highly efficient for the full duration of the study and for 1 month after the end of treatment, as described below:

    1. Cessation of menses for at least 12 months due to ovarian failure,
    2. Surgical sterilization such as bilateral oopherectomy, hysterectomy, or medically documented ovarian failure
    3. If requested by local IRB regulations and/or National laws, sexual abstinence may be considered adequate (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient)
    4. Using a highly effective nonhormonal method of contraception (bilateral tubal occlusion, vasectomized partner, or intra-uterine device)
    5. Double contraception with barrier AND highly effective hormonal method of contraception (oral, intravaginal, or transdermal combined estrogen and progestogen hormonal contraception associated with inhibition of ovulation; oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; or intrauterine hormone-releasing system). The hormonal contraception must be started at least 1 month prior to Randomization.
  4. Histological confirmation of steatohepatitis on a diagnostic liver by central reading of the slides (biopsy obtained within 6 months prior to randomization or during the screening period) with at least 1 in each component of the NAS score (steatosis scored 0-3, ballooning degeneration scored 0-2, and lobular inflammation scored 0-3).
  5. NAS score ≥4.
  6. Fibrosis stage of 1 or greater and below 4, according to the NASH CRN fibrosis staging system.
  7. Stable dose of vitamin E, polyunsaturated fatty acids, or ursodeoxycholic acid from at least 6 months prior to diagnostic liver biopsy
  8. For participants with type 2 diabetes, glycemia must be controlled. If glycemia is controlled by antidiabetic drugs, change in anti-diabetic therapy must follow these requirements:

    1. No qualitative change 6 months prior to diagnostic liver biopsy up to Randomization (i.e., implementation of a new anti-diabetic therapy) for participants treated with metformin, gliptins, sulfonylureas, sodium/glucose cotransporter (SGLT) 2 inhibitors, glucagon-like peptide (GLP)-1 agonists, or insulin. Dose changes of these medications are allowed in the 6 months prior to diagnostic liver biopsy, except for GLP-1 agonists, which must remain on stable dose in the 6 months prior to diagnostic liver biopsy.
    2. No implementation of GLP-1 agonists and SGLT2 inhibitors up to 72 weeks of treatment (Visit 7).

Initiation of any other antidiabetic drugs is allowed after Randomization based on treating physicians' judgment, except for glitazones which are prohibited 6 months prior to diagnostic liver biopsy until the end of treatment.

Exclusion criteria

Exclusion Criteria:

  1. Known heart failure (Grade I to IV of classification).
  2. History of efficient bariatric surgery within 5 years prior to screening.
  3. Uncontrolled hypertension during the Screening Period despite optimal antihypertensive therapy
  4. Type 1 diabetes participants .
  5. Participants with decompensated diabetes (>9%).
  6. Participants with a history of acute cardiac event within 6 months prior to screening
  7. Weight loss of more than 5% within 6 months prior to randomization
  8. Compensated and decompensated cirrhosis
  9. Current or recent history (\<5 years) of significant alcohol consumption
  10. Pregnant or lactating females or females planning to become pregnant during the study period.
  11. Other well documented causes of chronic liver disease according to standard diagnostic procedures
  12. Participants with previous exposure to Elafibranor
  13. Prohibited concomitant medication
  14. Any medical conditions that may diminish to less than 2 years including known cancers.
  15. Evidence of any other unstable or untreated clinically significant immunological, endocrine, hematological, gastrointestinal, neurological, neoplastic or psychiatric disease.
  16. Mental instability or incompetence, such that the validity of or ability to be compliant with the study is uncertain.
  17. Participants with biological criteria exclusion as per effective protocol
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,157 participants (actual)

Study arms

  • Experimental
    120 mg Elafibranor

    Coated tablets dosed at 120mg Elafibranor; oral administration; one tablet per day before breakfast with a glass of water

    Drug: Elafibranor

  • Placebo comparator
    Placebo

    Coated placebo tablets; oral administration; one tablet per day before breakfast with a glass of water

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis

    To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants with fibrosis by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving NASH resolution without worsening of fibrosis. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurement at 72 weeks

  2. Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes

    Composite long-term outcome measured by the number of participants with the onset of any of the adjudicated events, composed of death due to any cause, histological liver cirrhosis, and the full list of portal hypertension/cirrhosis related events as follows: liver transplantation; model for end stage liver disease (MELD) score greater than or equal to 15 for participants with baseline score less than or equal to 12, and onset of variceal bleeding requiring hospitalization, hepatic encephalopathy with West Haven/Conn score greater than or equal to 2 and requiring hospitalization, spontaneous bacterial peritonitis, and ascites requiring treatment. The MELD scale ranges from 6 to 40, showing how much a participant needs a liver transplant: higher number is more urgent. The West Haven/Conn scale is 5-point (0 to 4) grading severity of hepatic encephalopathy: higher score means worse hepatic encephalopathy. This outcome measure is for the long-term endpoint analysis.

    Time frame: From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant)

Secondary outcomes

  1. Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage

    To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving improvement of liver fibrosis of at least 1 stage according to NASH Clinical Research Network (CRN) Scoring. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements at 72 weeks

  2. Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

    Hemoglobin A1c (HbA1c) were tested at Week 72. Changes from baseline in HbA1c at Week 72 were evaluated. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

  3. Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

    High-density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

  4. Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

    Low-density lipoprotein (LDL) cholesterol was tested at Week 72. Changes from baseline in LDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

  5. Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants

    Homeostatic model assessment-IR (HOMA-IR) was tested at Week 72. Changes from baseline in HOMA-IR were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

  6. Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

    Non-high density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in non-HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

  7. Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

    Triglycerides was tested at Week 72. Changes from baseline in triglycerides were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

    Time frame: Measurements after 72 weeks of treatment and up to study termination

07

Results

Posted Mar 23, 2022
Limitations and caveats
The study was prematurely terminated based upon limited efficacy at time of the interim analysis, not due to safety concerns, and the conclusion that there would be limited benefit for participants to continue in the trial. Therefore, the results for efficacy endpoints other than the primary and key secondary endpoints are not presented in the disclosure of these results.

Participant flow

The version 3 protocol for Brazil is included in the uploaded documents as it was part of the pre-specified plan, but this country was not used as part of the study.

Participant flow — Overall Study
Milestone120 mg ElafibranorPlacebo
Started1437720
Full intent-to-treat population1437720
Full safety population1433717
Completed00
Not completed1437720
Withdrew: Randomized and not treated (due to non-compliance with protocol)43
Withdrew: Administrative reasons by sponsor1251616
Withdrew: Death43
Withdrew: Endpoint event5224
Withdrew: Lost to follow-up2211
Withdrew: Protocol violation1515
Withdrew: Adverse event20
Withdrew: Withdrawal by subject8545
Withdrew: Investigator decision11
Withdrew: Follow-up not possible12

Outcome measures

PrimaryNumber of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis

To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants with fibrosis by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving NASH resolution without worsening of fibrosis. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurement at 72 weeks
Reported as:
Count of participants · Participants
Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis
Participants120 mg ElafibranorPlacebo
Number of Elafibranor-treated Participants Relative to Placebo Achieving Resolution of Nonalcoholic Steatohepatitis Without Worsening of Fibrosis13852
Statistical analysis
  • 120 mg Elafibranor vs Placebo · Regression, Logistic · p = 0.0659 · Mean difference (net): 0.043 · 95% CI -0.003 to 0.090test is 2-sided, alpha=0.01
PrimaryTime to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes

Composite long-term outcome measured by the number of participants with the onset of any of the adjudicated events, composed of death due to any cause, histological liver cirrhosis, and the full list of portal hypertension/cirrhosis related events as follows: liver transplantation; model for end stage liver disease (MELD) score greater than or equal to 15 for participants with baseline score less than or equal to 12, and onset of variceal bleeding requiring hospitalization, hepatic encephalopathy with West Haven/Conn score greater than or equal to 2 and requiring hospitalization, spontaneous bacterial peritonitis, and ascites requiring treatment. The MELD scale ranges from 6 to 40, showing how much a participant needs a liver transplant: higher number is more urgent. The West Haven/Conn scale is 5-point (0 to 4) grading severity of hepatic encephalopathy: higher score means worse hepatic encephalopathy. This outcome measure is for the long-term endpoint analysis.

Time frame:
From first randomization up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant)
Reported as:
Count of participants · Participants
Time to Long-term Outcome Composed of All-cause Mortality, Cirrhosis, and Liver-related Clinical Outcomes
Participants120 mg ElafibranorPlacebo
Baseline — Events00
Baseline — Censored00
Baseline — No events or not censored1437720
6 months — Events11
6 months — Censored4826
6 months — No events or not censored1388693
12 months — Events11
12 months — Censored15982
12 months — No events or not censored1277637
18 months — Events5328
18 months — Censored374195
18 months — No events or not censored1010497
24 months — Events5631
24 months — Censored609301
24 months — No events or not censored772388
30 months — Events5731
30 months — Censored778393
30 months — No events or not censored602296
36 months — Events6032
36 months — Censored1049531
36 months — No events or not censored328157
42 months — Events6132
42 months — Censored1293652
42 months — No events or not censored8336
48 months — Events6132
48 months — Censored1374687
48 months — No events or not censored21
54 months — Events6132
54 months — Censored1376688
54 months — No events or not censored00
Statistical analysis
  • 120 mg Elafibranor vs Placebo · Cox proportional hazard: 0.950 · 95% CI 0.619 to 1.457No formal test due to the early termination of the study.
SecondaryNumber of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage

To evaluate the effect of Elafibranor compared to placebo on liver histology in nonalcoholic steatohepatitis (NASH) participants by assessing the following endpoint: The number of Elafibranor-treated participants relative to placebo achieving improvement of liver fibrosis of at least 1 stage according to NASH Clinical Research Network (CRN) Scoring. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements at 72 weeks
Reported as:
Count of participants · Participants
Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage
Participants120 mg ElafibranorPlacebo
Number of Elafibranor-treated Participants Relative to Placebo Achieving Improvement of Fibrosis of at Least 1 Stage17679
SecondaryChange From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

Hemoglobin A1c (HbA1c) were tested at Week 72. Changes from baseline in HbA1c at Week 72 were evaluated. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · mmol/L
Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
mmol/L120 mg ElafibranorPlacebo
Change From Baseline of Hemoglobin A1c (HbA1c) in Diabetic Participants After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo0.03 (-0.19 to 0.25)-0.01 (-0.24 to 0.23)
SecondaryChange From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

High-density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · mmol/L
Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
mmol/L120 mg ElafibranorPlacebo
Change From Baseline of High-density Lipoprotein (HDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo-0.036 (-0.050 to -0.021)-0.052 (-0.073 to -0.032)
SecondaryChange From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

Low-density lipoprotein (LDL) cholesterol was tested at Week 72. Changes from baseline in LDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · mmol/L
Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
mmol/L120 mg ElafibranorPlacebo
Change From Baseline of Low-density Lipoprotein (LDL) Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo-0.250 (-0.295 to -0.204)-0.217 (-0.282 to -0.151)
SecondaryChange From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants

Homeostatic model assessment-IR (HOMA-IR) was tested at Week 72. Changes from baseline in HOMA-IR were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · index
Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants
index120 mg ElafibranorPlacebo
Change From Baseline of Homeostatic Model Assessment-IR (HOMA-IR) After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo in Non-diabetic Participants-0.789 (-2.979 to 1.402)-0.930 (-3.347 to 1.486)
SecondaryChange From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

Non-high density lipoprotein (HDL) cholesterol was tested at Week 72. Changes from baseline in non-HDL cholesterol were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · mmol/L
Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
mmol/L120 mg ElafibranorPlacebo
Change From Baseline of Non-high Density Lipoprotein Cholesterol After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo-0.445 (-0.499 to -0.392)-0.271 (-0.348 to -0.195)
SecondaryChange From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo

Triglycerides was tested at Week 72. Changes from baseline in triglycerides were evaluated at Week 72. As the primary efficacy objective was not met, the secondary efficacy endpoints were not formally tested. This outcome measure is for the surrogate endpoint analysis.

Time frame:
Measurements after 72 weeks of treatment and up to study termination
Reported as:
Least squares mean · mmol/L
Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo
mmol/L120 mg ElafibranorPlacebo
Change From Baseline of Triglycerides After 72 Weeks of Treatment in Elafibranor-treated Participants Relative to Placebo-0.466 (-0.537 to -0.395)-0.148 (-0.249 to -0.046)

Adverse events

Collected over Adverse event information was collected at every study visit from screening up to early termination of the study corresponding to 54 months (54 months being the longest duration for any given participant) plus 30 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
120 mg Elafibranor6/1,437 (0.4%)190/1,433 (13.3%)1,227/1,433 (85.6%)
Placebo3/720 (0.4%)95/717 (13.2%)601/717 (83.8%)
Most frequent serious events
Showing 10 of 280
Most frequent serious events
Event120 mg ElafibranorPlacebo
Atrial fibrillationCardiac disorders2/14335/717
ArthralgiaMusculoskeletal and connective tissue disorders0/14335/717
PneumoniaInfections and infestations6/14333/717
DiarrhoeaGastrointestinal disorders2/14333/717
Abdominal painGastrointestinal disorders1/14333/717
Urinary tract infectionInfections and infestations2/14333/717
SyncopeNervous system disorders2/14333/717
AsthmaRespiratory, thoracic and mediastinal disorders2/14333/717
Acute myocardial infarctionCardiac disorders5/14330/717
Non-cardiac chest painGeneral disorders5/14332/717
Most frequent other events
Showing 10 of 18
Most frequent other events
Event120 mg ElafibranorPlacebo
ArthralgiaMusculoskeletal and connective tissue disorders160/143381/717
Urinary tract infectionInfections and infestations145/143377/717
DiarrhoeaGastrointestinal disorders148/143368/717
NauseaGastrointestinal disorders140/143350/717
NasopharyngitisInfections and infestations134/143352/717
Back painMusculoskeletal and connective tissue disorders120/143360/717
Type 2 diabetes mellitusMetabolism and nutrition disorders102/143358/717
InfluenzaInfections and infestations115/143354/717
Upper respiratory tract infectionInfections and infestations107/143346/717
FatigueGeneral disorders103/143349/717

Baseline characteristics

Age, Continuous
Age, Continuous(years)120 mg ElafibranorPlaceboTotal
Mean54.0 ± 11.7854.4 ± 11.6354.1 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)120 mg ElafibranorPlaceboTotal
Female622308930
Male8154121227
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)120 mg ElafibranorPlaceboTotal
Hispanic or Latino336177513
Not Hispanic or Latino10895321621
Unknown or Not Reported121123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)120 mg ElafibranorPlaceboTotal
American Indian or Alaska Native819
Asian532780
Native Hawaiian or Other Pacific Islander336
Black or African American281038
White12346141848
More than one race9349142
Unknown or Not Reported181634
Weight
Weight(kg)120 mg ElafibranorPlaceboTotal
Mean98.0 ± 21.9096.3 ± 20.8497.4 ± 21.56
Height
Height(cm)120 mg ElafibranorPlaceboTotal
Mean169.1 ± 10.48168.8 ± 10.23169.0 ± 10.39
BMI
BMI(kg/m^2)120 mg ElafibranorPlaceboTotal
Mean34.1 ± 6.1333.6 ± 5.7733.9 ± 6.01
Waist Circumference
Waist Circumference(cm)120 mg ElafibranorPlaceboTotal
Mean111.9 ± 14.19110.4 ± 13.48111.4 ± 13.97

6 further baseline measures are reported on the registry.

08

Study locations

326 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35294, United States
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • The Institute for Liver Health
    Chandler, Arizona 85224, United States
  • The Institute for Liver Health
    Glendale, Arizona 85306, United States
  • Banner University Medical Center Phoenix
    Phoenix, Arizona 85006, United States
  • Dignity Health St. Joseph's Hospital
    Phoenix, Arizona 85013, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • Institute for Liver Health
    Tucson, Arizona 85711, United States
  • Adobe Clinical Research, LLC
    Tucson, Arizona 85712, United States
  • The University of Arizona College of Medicine Liver Research Institute
    Tucson, Arizona 85724-0001, United States
  • Liver Wellness Center
    Little Rock, Arkansas 72205, United States
  • GW Research, Inc.
    Chula Vista, California 91910, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • University of California, San Francisco, Fresno Community Regional Medical Center
    Fresno, California 93701-2302, United States
  • Fresno Clinical Research Center
    Fresno, California 93720, United States
  • University of California, San Francisco, Fresno Community Regional Medical Center
    Fresno, California 93721, United States
  • Scripps Clinic Torrey Pines
    La Jolla, California 92037, United States
  • University of California - San Diego
    La Jolla, California 92037, United States
  • Loma Linda University Medical Center - Transplantation Insitute
    Loma Linda, California 92354, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • Keck Hospital of USC
    Los Angeles, California 90033, United States
  • Ruane Clinical Research Group Inc.
    Los Angeles, California 90036, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Gastrointestinal Biosciences Clinical Trials LLC
    Los Angeles, California 90067, United States
  • Veterans Affaires Greater Los Angeles Healthcare System, West LA VA Medical Center
    Los Angeles, California 90073, United States
  • Veterans Affairs Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • Alliance Clinical Research
    Oceanside, California 92056, United States
  • National Research Institute
    Panorama City, California 91402, United States
  • Alliance Clinical Research
    Poway, California 92064, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • University of California, San Diego Airway Research and Clinical Trials Center
    San Diego, California 92103, United States
  • Medical Associates Research Group, Inc.
    San Diego, California 92123, United States
  • VA San Diego HealthCare System
    San Diego, California 92161, United States
  • Quest Clinical Research
    San Francisco, California 94115, United States
  • Sutter West Bay Hospitals dba California Pacific Medical Center
    San Francisco, California 94115, United States
  • University of California, San Francisco, Medical Center at Parnassus
    San Francisco, California 94143, United States
  • Ventura Clinical Trials
    Ventura, California 93003, United States
  • South Denver Gastroenterology
    Englewood, Colorado 80113, United States
  • Yale University School of Medicine, Section of Digestive Diseases
    New Haven, Connecticut 65200, United States
  • Georgetown University Hospitals
    Washington, District of Columbia 20007, United States
  • Sibley Memorial Hospital
    Washington, District of Columbia 20016, United States
  • Excel Medical Clinical Trials LLC
    Boca Raton, Florida 33434, United States
  • Integrity Clinical Research LLC
    Doral, Florida 33166, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • Nature Coast Clinical Research
    Inverness, Florida 34452, United States
  • Mayo Clinic Hospital
    Jacksonville, Florida 32224, United States
  • Florida Digestive Health Specialists, LLP
    Lakewood Ranch, Florida 34211-4930, United States
  • Atlantic Gastroenterology Associates, LLC
    Lakewood Ranch, Florida 34211, United States
  • Miami VA Healthcare System
    Miami, Florida 33125-1624, United States
  • University of Miami - Miller School of Medicine
    Miami, Florida 33136, United States
  • University of Miami - Schiff Center for Liver Diseases
    Miami, Florida 33136, United States
  • South Florida Center of Gastroenterology, PA
    Wellington, Florida 33414, United States
  • Florida Medical Clinic, PA
    Zephyrhills, Florida 33542, United States
  • Summit Clinical Research
    Athens, Georgia 30607, United States
  • Emory University Hospital Midtown
    Atlanta, Georgia 30308, United States
  • Piedmont Atlanta Hospital
    Atlanta, Georgia 30309, United States
  • Atlanta Medical Center, Inc.
    Atlanta, Georgia 30312, United States
  • Gastrointestinal Specialists of Georgia, PC
    Marietta, Georgia 30060-8949, United States
  • The Queen's Medical Center
    Honolulu, Hawaii 96813, United States
  • Northwestern Memorial Hospital - Arkes Family Pavilion
    Chicago, Illinois 60611, United States
  • Rush University Medical Center
    Chicago, Illinois 60637, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Loyola University Chicago
    Maywood, Illinois 60153, United States
  • Gastroenterology Associates of Hazard
    Hazard, Kentucky 41701, United States
  • University of Kentucky Chandler Medical Center
    Lexington, Kentucky 40536, United States
  • University of Louisville Medical / Dental Complex
    Louisville, Kentucky 40202, United States
  • Tulane University School of Medicine
    New Orleans, Louisiana 70112, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21205, United States
  • Walter Reed National Military Medical Center
    Bethesda, Maryland 20889, United States
  • Kaiser Permanente Shady Grove Medical Center
    Rockville, Maryland 20850, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center (BIDMC)
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Memorial Medical Center
    Worcester, Massachusetts 06155, United States
  • Henry Ford Health System, Division of Gastroenterology & Hepatology
    Detroit, Michigan 48202, United States
  • Gastrointestinal Associates & Endoscopy Center
    Flowood, Mississippi 39232, United States
  • University of Mississippi Medical Center
    Jackson, Mississippi 39216, United States
  • St. Luke's Liver Transplant & Specialist
    Kansas City, Missouri 64111, United States
  • Kansas City VA Medical Center
    Kansas City, Missouri 64128, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Saint Louis University School of Medicine
    Saint Louis, Missouri 63104, United States
  • Rutgers, Robert Wood Johnson Medical School
    New Brunswick, New Jersey 89030, United States
  • Rutgers, New Jersey Medical School
    Newark, New Jersey 07103, United States
  • Southwest Gastroenterology Associates
    Albuquerque, New Mexico 87109, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • University at Buffalo, Clinical and Translational Research Center
    Buffalo, New York 14203, United States
  • Hofstra Northwell School of Medicine
    Manhasset, New York 11030, United States
  • Concorde Medical Group
    New York, New York 10016, United States
  • New York University Langone Medical Center
    New York, New York 10016, United States
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • New York-Presbyterian Hospital - Columbia University Medical Center
    New York, New York 10032, United States
  • Beth Israel Medical Center
    New York, New York 45267, United States
  • Premier Medical Group
    Poughkeepsie, New York 12601, United States
  • Asheville Gastroenterology Associates
    Asheville, North Carolina 28801, United States
  • UNC Health Care System
    Chapel Hill, North Carolina 27599, United States
  • Carolinas Medical Center
    Charlotte, North Carolina 28204, United States
  • Duke Gastroenterology
    Durham, North Carolina 22710, United States

Showing the first 100 of 326 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2016, a primary completion of Oct 2020 and a completion of Oct 2020. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2022, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2016
First posted
Mar 10, 2016
Start
Mar 2016
Primary completionActual
Oct 28, 2020
CompletionActual
Oct 28, 2020
Results first posted
Mar 23, 2022
Last update
Mar 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02704403
Lead sponsor
Genfit
Responsible party
Sponsor
First posted
Mar 10, 2016
Start date
Mar 2016
Primary completion
Oct 28, 2020
Completion
Oct 28, 2020
Results posted
Mar 23, 2022
Last update
Mar 23, 2022

Study contacts

Carol Addy, MD MMSc
study director · Genfit

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elifibranor

Start the discussion